MacroGenics Announces Participation in Three Upcoming Investor Conferences
August 30 2018 - 6:05PM
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage
biopharmaceutical company focused on discovering and developing
innovative monoclonal antibody-based therapeutics for the treatment
of cancer, today announced that the Company's management will
participate in three investor conferences in September. These
conferences include:
- H.C. Wainwright & Co. 20th Annual Global Investment
Conference – MacroGenics’ management will participate in the
conference and provide a corporate update on September 5, 2018, at
8:45am ET in New York City.
- Citi’s 13th Annual Biotech Conference – MacroGenics’
management will participate in the conference and Dr. Scott Koenig,
M.D., Ph.D., President and Chief Executive Officer, will
participate in a panel discussion entitled “Landscape in
Immuno-Oncology and Bi-Specific Antibodies” on September 6, 2018,
at 9:00am ET in Boston.
- Morgan Stanley 16th Annual Global Healthcare Conference –
MacroGenics’ management will participate in the conference,
including a fireside chat on September 12, 2018, at 9:55am ET in
New York City.
A webcast of the H.C. Wainwright & Co. and Morgan Stanley
conference presentations may be accessed under "Events &
Presentations" in the Investor Relations section of MacroGenics'
website at http://ir.macrogenics.com/events.cfm. The Company will
maintain archived replays of these webcasts on its website for 30
days after the conference.
About MacroGenics, Inc.
MacroGenics is a clinical-stage biopharmaceutical company
focused on discovering and developing innovative monoclonal
antibody-based therapeutics for the treatment of cancer. The
Company generates its pipeline of product candidates primarily from
its proprietary suite of next-generation antibody-based technology
platforms, which have applicability across broad therapeutic
domains. The combination of MacroGenics' technology platforms and
protein engineering expertise has allowed the Company to generate
promising product candidates and enter into several strategic
collaborations with global pharmaceutical and biotechnology
companies. For more information, please see the Company's website
at www.macrogenics.com. MacroGenics, the MacroGenics logo and DART
are trademarks or registered trademarks of MacroGenics, Inc.
###
Contacts:
Jim Karrels, Senior Vice President, CFO
MacroGenics, Inc.
1-301-251-5172, info@macrogenics.com
Karen Sharma, Senior Vice President
MacDougall Biomedical Communications
1-781-235-3060, ksharma@macbiocom.com
MacroGenics (NASDAQ:MGNX)
Historical Stock Chart
From Aug 2024 to Sep 2024
MacroGenics (NASDAQ:MGNX)
Historical Stock Chart
From Sep 2023 to Sep 2024